Skip to main content
Scinai Immunotherapeutics Ltd. logo

Scinai Immunotherapeutics Ltd. — Investor Relations & Filings

Ticker · SCNI ISIN · US09073Q3039 US Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2024-09-09 Regulatory Filings
Country US United States of America
Listing US SCNI

About Scinai Immunotherapeutics Ltd.

https://www.scinai.com/

Scinai Immunotherapeutics Ltd. is a clinical-stage biopharmaceutical company operating through two complementary business units. Its internal research and development division focuses on developing innovative biological products for inflammation and immunology (I&I), targeting autoimmune and infectious diseases. The core of its therapeutic pipeline is a platform of Alpaca-derived nanosized antibodies (NanoAbs or VHH-antibodies), developed for conditions such as psoriasis and asthma. The company's second unit, Scinai Bioservices, is a Contract Development and Manufacturing Organization (CDMO). It provides end-to-end services to biotech companies, supporting drug development from early research and process development through to cGMP-compliant manufacturing for clinical trials up to Phase 3.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Scinai Immunotherapeutics Ltd. It includes an amendment to a previous Form 6-K to furnish unaudited interim condensed consolidated financial statements as of June 30, 2024. The document length is 2922 characters, which is relatively short and includes references to exhibits containing financial statements and a press release. The document itself does not contain the full interim financial report but rather furnishes it as an exhibit. According to the rules, if a document is short and states that a report is furnished as an exhibit, it should be classified as a Regulatory Filing (RNS) rather than the report itself (IR). Therefore, this filing is best classified as a Regulatory Filing (RNS).
2024-09-09 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains an explanatory note about a press release regarding Nasdaq compliance and includes the press release as an exhibit. The document is relatively short (2267 characters) and primarily serves to furnish a press release rather than provide detailed financial data or a full report. It does not contain financial statements or substantive financial analysis. Therefore, it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a certification or officer attestation. Given the nature of the filing and its content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-08-29 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It announces the closing of a Loan Restructuring Agreement converting debt to preferred equity and includes a press release as an exhibit. The document is short (2191 characters) and primarily serves as an announcement of this event rather than a detailed financial report. It does not contain comprehensive financial statements or detailed analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-08-21 English
AMENDMENT 3 TO SCHEDULE 13G
Major Shareholding Notification
2024-08-20 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains an explanatory note about a press release announcing a $2 million private equity commitment agreement. The document is short (2104 characters) and primarily serves to furnish a press release as Exhibit 99.1. There are no detailed financial statements or substantive financial data presented. The document is an announcement of a financing update rather than the financing update itself. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it does not contain the full financing report but rather a notice and press release related to financing activity.
2024-08-20 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It references a press release announcing the publication of Q2 2024 financial results and a business update, but the document itself is a brief report furnishing that press release as Exhibit 99.1. The document length is short (2004 characters), and it does not contain the actual financial statements or detailed financial data, only a notice of the press release. According to the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such filings that do not contain substantive financial data themselves.
2024-08-15 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.